Gilles Vassal

发表

Characterisation of the 4q12 amplicon in pediatric gliomas

Paul Workman, Michael D. Taylor, Steven K. Baker, 2008 .

Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial

Marie-Cécile Le Deley, Charles Ferté, Philippe Vielh, 2016, Clinical Cancer Research.

Breakpoint Features of Genomic Rearrangements in Neuroblastoma with Unbalanced Translocations and Chromothripsis

Emmanuel Barillot, Gudrun Schleiermacher, Isabelle Janoueix-Lerosey, 2013, PloS one.

Challenges for children and adolescents with cancer in Europe: The SIOP-Europe agenda

Ruth Ladenstein, Maria Grazia Valsecchi, Samira Essiaf, 2014, Pediatric blood & cancer.

Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array

Philippe Dessen, Stefan Michiels, Lajos Pusztai, 2009, Clinical Cancer Research.

Molecular and Phenotypic Characterisation of Paediatric Glioma Cell Lines as Models for Preclinical Drug Development

Paul Workman, Darren Hargrave, Chris Jones, 2009, PloS one.

Quantification of dimethyl-ifosfamide and its N-deschloropropylated metabolites in mouse plasma by liquid chromatography-tandem mass spectrometry.

Gilles Vassal, A. Paci, G. Vassal, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

Günter Schreier, Ruth Ladenstein, Henrik Schroeder, 2017, The Lancet. Oncology.

Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy

Jacques Robert, Gilles Vassal, G. Vassal, 2008, Pathology & Oncology Research.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Marie-Cécile Le Deley, Stefan Michiels, Caroline Even, 2017, Cancer discovery.

In vivo antitumor activity of S16020, a topoisomerase II inhibitor, and doxorubicin against human brain tumor xenografts

Jacques Grill, Gilles Vassal, C. Sainte-Rose, 2003, Cancer Chemotherapy and Pharmacology.

Implementation of mechanism of action biology-driven early drug development for children with cancer.

Gudrun Schleiermacher, Hubert Caron, Birgit Geoerger, 2016, European journal of cancer.

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer

Pierre Validire, Yudi Pawitan, Angel Porgador, 2015, Oncotarget.

The Chemokine Receptor CXCR4 Strongly Promotes Neuroblastoma Primary Tumour and Metastatic Growth, but not Invasion

Nicole Gross, Curzio Ruegg, Gilles Vassal, 2007, PloS one.

EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines

Paul Workman, Jorge S. Reis-Filho, Darren Hargrave, 2009, Clinical Cancer Research.